Related Experiment Video
Updated: Jul 5, 2026
Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Recombinant plasmid constructs expressing gene for antimicrobial peptide melittin for the therapy of Mycoplasma and
V N Lazarev1, M M Shkarupeta, E S Kostryukova
1Laboratory of Gene Engineering, Institute of Physicochemical Medicine, Federal Agency on Health Care and Social Development, Moscow.
Abstract:
In view of growing number of pathogenic microbial strain resistant to routine antibiotics, antimicrobial peptides become promising agents for the therapy of infectious diseases. We studied in vivo effects of melittin, an antimicrobial peptide expressed in a recombinant plasmid vector, on infection with urogenital pathogens Chlamydia trachomatis, Mycoplasma hominis, and Mycoplasma gallisepticum. We obtained recombinant plasmid constructs, where melittin gene is under the control of tetracycline-dependent human cytomegalovirus promoter. Inhibition of experimental C. trachomatis, M. hominis, and M. gallisepticum infection after administration of recombinant plasmid vectors expressing melittin gene to BALB/c mice was demonstrated.
Insights
Antimicrobial peptides like melittin show promise against antibiotic-resistant infections. Recombinant melittin gene therapy effectively inhibited Chlamydia trachomatis and Mycoplasma infections in mice.
Area of Science:
- Microbiology
- Biotechnology
- Infectious Diseases
Background:
- Antibiotic resistance in pathogenic microbes necessitates novel therapeutic strategies.
- Antimicrobial peptides (AMPs) are emerging as potential alternatives to conventional antibiotics.
- Melittin, a potent AMP, has demonstrated broad-spectrum antimicrobial activity.
Purpose of the Study:
- To investigate the in vivo efficacy of a recombinant melittin gene against urogenital pathogens.
- To evaluate the therapeutic potential of plasmid-based melittin delivery in a mouse model.
Main Methods:
- Construction of recombinant plasmid vectors encoding the melittin gene under a tetracycline-dependent promoter.
- Administration of these vectors to BALB/c mice experimentally infected with Chlamydia trachomatis, Mycoplasma hominis, and Mycoplasma gallisepticum.
- Assessment of infection inhibition following vector administration.
Main Results:
- Successful generation of recombinant plasmid constructs for melittin expression.
- Demonstrated significant inhibition of experimental C. trachomatis infections.
- Observed inhibition of experimental M. hominis and M. gallisepticum infections.
Conclusions:
- Recombinant plasmid vectors expressing melittin are effective in controlling urogenital pathogen infections in vivo.
- Melittin gene therapy represents a promising approach for combating antibiotic-resistant microbial infections.
- Further research into AMP-based therapies is warranted for infectious disease treatment.
